|
1.
|
Lynch HT and de la Chapelle A: Hereditary
colorectal cancer. N Engl J Med. 348:919–932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Calvert PM and Frucht H: The genetics of
colorectal cancer. Ann Intern Med. 137:603–612. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Lynch HT, Lanspa S, Smyrk T, Boman B,
Watson P and Lynch J: Hereditary nonpolyposis colorectal cancer
(Lynch syndromes I & II). Genetics, pathology, natural history
and cancer control, Part I. Cancer Genet Cytogenet. 53:143–160.
1991.
|
|
4.
|
Terdiman JP, Conrad PG and Sleisenger MH:
Genetic testing in hereditary colorectal cancer: indications and
procedures. Am J Gastroenterol. 94:2344–2356. 1999. View Article : Google Scholar
|
|
5.
|
Cheung P and Lau P: Epigenetic regulation
by histone methylation and histone variants. Mol Endocrinol.
19:563–573. 2005. View Article : Google Scholar
|
|
6.
|
Hoffmann MJ and Schulz WA: Causes and
consequences of DNA hypomethylation in human cancer. Biochem Cell
Biol. 83:296–321. 2005. View
Article : Google Scholar
|
|
7.
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Holliday R: Epigenetics: a historical
overview. Epigenetics. 1:76–80. 2006. View Article : Google Scholar
|
|
9.
|
Esteller M: Relevance of DNA methylation
in the management of cancer. Lancet Oncol. 4:351–358. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Robertson KD and Wolffe AP: DNA
methylation in health and disease. Nat Rev Genet. 1:11–19. 2000.
View Article : Google Scholar
|
|
11.
|
Warnecke PM and Bestor TH: Cytosine
methylation and human cancer. Curr Opin Oncol. 12:68–73. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Hoffman AR, Vu TH and Hu J: Mechanisms of
genomic imprinting. Growth Horm IGF Res. 10:S18–S19. 2000.
View Article : Google Scholar
|
|
13.
|
Jenuwein T and Allis CD: Translating the
histone code. Science. 293:1074–1080. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Kondo Y and Issa JP: Epigenetic changes in
colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
View Article : Google Scholar
|
|
15.
|
Sasaki H, Allen ND and Surani MA: DNA
methylation and genomic imprinting in mammals. EXS. 64:469–486.
1993.PubMed/NCBI
|
|
16.
|
Efstratiadis A: Parental imprinting of
autosomal mammalian genes. Curr Opin Genet Dev. 4:265–280. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Reik W and Walter J: Genomic imprinting:
parental influence on the genome. Nat Rev Genet. 2:21–32. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Constancia M, Pickard B, Kelsey G and Reik
W: Imprinting mechanisms. Genome Res. 8:881–900. 1998.
|
|
19.
|
Pollak M: Insulin-like growth factor
physiology and neoplasia. Growth Horm IGF Res. 10:S6–S7. 2000.
View Article : Google Scholar
|
|
20.
|
Pavelic K, Bukovic D and Pavelic J: The
role of insulin-like growth factor 2 and its receptors in human
tumors. Mol Med. 8:771–780. 2002.PubMed/NCBI
|
|
21.
|
Van Dijk MA, van Schaik FM, Bootsma HJ,
Holthuizen P and Sussenbach JS: Initial characterization of the
four promoters of the human insulin-like growth factor II gene. Mol
Cell Endocrinol. 81:81–94. 1991.
|
|
22.
|
Kinouchi Y, Hiwatashi N, Higashioka S,
Nagashima F, Chida M and Toyota T: Relaxation of imprinting of the
insulin-like growth factor II gene in colorectal cancer. Cancer
Lett. 107:105–108. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Sussenbach JS, Steenbergh PH, Jansen E, et
al: Structural and regulatory aspects of the human genes encoding
IGF-I and -II. Adv Exp Med Biol. 293:1–14. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Issa JP, Vertino PM, Boehm CD, Newsham IF
and Baylin SB: Switch from monoallelic to biallelic human IGF2
promoter methylation during aging and carcinogenesis. Proc Natl
Acad Sci USA. 93:11757–11762. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
DeChiara TM, Robertson EJ and Efstratiadis
A: Parental imprinting of the mouse insulin-like growth factor II
gene. Cell. 64:849–859. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Giannoukakis N, Deal C, Paquette J,
Goodyer CG and Polychronakos C: Parental genomic imprinting of the
human IGF2 gene. Nat Genet. 4:98–101. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Henry I, Bonaiti-Pellie C, Chehensse V, et
al: Uniparental paternal disomy in a genetic cancer-predisposing
syndrome. Nature. 351:665–667. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Nicholls RD, Knoll JH, Butler MG, Karam S
and Lalande M: Genetic imprinting suggested by maternal
heterodisomy in nondeletion Prader-Willi syndrome. Nature.
342:281–285. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Cerrato F, Sparago A, Verde G, et al:
Different mechanisms cause imprinting defects at the IGF2/H19 locus
in Beckwith-Wiedemann syndrome and Wilms’ tumour. Hum Mol Genet.
17:1427–1435. 2008.PubMed/NCBI
|
|
30.
|
Rainier S, Johnson LA, Dobry CJ, Ping AJ,
Grundy PE and Feinberg AP: Relaxation of imprinted genes in human
cancer. Nature. 362:747–749. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Takano Y, Shiota G and Kawasaki H:
Analysis of genomic imprinting of insulin-like growth factor 2 in
colorectal cancer. Oncology. 59:210–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Cui H, Horon IL, Ohlsson R, Hamilton SR
and Feinberg AP: Loss of imprinting in normal tissue of colorectal
cancer patients with microsatellite instability. Nat Med.
4:1276–1280. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Kawakami K, Ruszkiewicz A, Bennett G, et
al: DNA hypermethylation in the normal colonic mucosa of patients
with colorectal cancer. Br J Cancer. 94:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Cui H, Cruz-Correa M, Giardiello FM, et
al: Loss of IGF2 imprinting: a potential marker of colorectal
cancer risk. Science. 299:1753–1755. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Ohta M, Sugimoto T, Seto M, et al: Genetic
alterations in colorectal cancers with demethylation of
insulin-like growth factor II. Hum Pathol. 39:1301–1308. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Cruz-Correa M, Cui H, Giardiello FM, et
al: Loss of imprinting of insulin growth factor II gene: a
potential heritable biomarker for colon neoplasia predisposition.
Gastroenterology. 126:964–970. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Cruz-Correa M, Zhao R, Oviedo M, et al:
Temporal stability and age-related prevalence of loss of imprinting
of the insulin-like growth factor-2 gene. Epigenetics. 4:114–118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Bartolomei MS, Zemel S and Tilghman SM:
Parental imprinting of the mouse H19 gene. Nature. 351:153–155.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Brannan CI, Dees EC, Ingram RS and
Tilghman SM: The product of the H19 gene may function as an RNA.
Mol Cell Biol. 10:28–36. 1990.PubMed/NCBI
|
|
40.
|
Kuhn EJ and Geyer PK: Genomic insulators:
connecting properties to mechanism. Curr Opin Cell Biol.
15:259–265. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Moore T, Constancia M, Zubair M, et al:
Multiple imprinted sense and antisense transcripts, differential
methylation and tandem repeats in a putative imprinting control
region upstream of mouse Igf2. Proc Natl Acad Sci USA.
94:12509–12514. 1997. View Article : Google Scholar
|
|
42.
|
Taniguchi T, Schofield AE, Scarlett JL,
Morison IM, Sullivan MJ and Reeve AE: Altered specificity of IGF2
promoter imprinting during fetal development and onset of Wilms
tumour. Oncogene. 11:751–756. 1995.PubMed/NCBI
|
|
43.
|
Sullivan MJ, Taniguchi T, Jhee A, Kerr N
and Reeve AE: Relaxation of IGF2 imprinting in Wilms tumours
associated with specific changes in IGF2 methylation. Oncogene.
18:7527–7534. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Ulaner GA, Vu TH, Li T, et al: Loss of
imprinting of IGF2 and H19 in osteosarcoma is accompanied by
reciprocal methylation changes of a CTCF-binding site. Hum Mol
Genet. 12:535–549. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Byun HM, Wong HL, Birnstein EA, Wolff EM,
Liang G and Yang AS: Examination of IGF2 and H19 loss of imprinting
in bladder cancer. Cancer Res. 67:10753–10758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Murphy SK, Huang Z, Wen Y, et al: Frequent
IGF2/H19 domain epigenetic alterations and elevated IGF2 expression
in epithelial ovarian cancer. Mol Cancer Res. 4:283–292. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Cui H, Onyango P, Brandenburg S, Wu Y,
Hsieh CL and Feinberg AP: Loss of imprinting in colorectal cancer
linked to hypomethylation of H19 and IGF2. Cancer Res.
62:6442–6446. 2002.PubMed/NCBI
|
|
48.
|
Monk D, Sanches R, Arnaud P, et al:
Imprinting of IGF2 P0 transcript and novel alternatively spliced
INS-IGF2 isoforms show differences between mouse and human. Hum Mol
Genet. 15:1259–1269. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Murrell A, Ito Y, Verde G, et al: Distinct
methylation changes at the IGF2-H19 locus in congenital growth
disorders and cancer. PLoS One. 3:e18492008. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Ito Y, Koessler T, Ibrahim AE, et al:
Somatically acquired hypomethylation of IGF2 in breast and
colorectal cancer. Hum Mol Genet. 17:2633–2643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Pantoja C, de Los Rios L, Matheu A,
Antequera F and Serrano M: Inactivation of imprinted genes induced
by cellular stress and tumorigenesis. Cancer Res. 65:26–33.
2005.PubMed/NCBI
|
|
52.
|
De la Chapelle A: Microsatellite
instability. N Engl J Med. 349:209–210. 2003.
|
|
53.
|
Ehrlich M: DNA methylation in cancer: too
much, but also too little. Oncogene. 21:5400–5413. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Alonso A, Moreno S, Valiente A, Artigas M,
Perez-Juana A and Ramos Arroyo MA: Genetic mechanisms in the
hereditary predisposition to colorectal cancer. An Sist Sanit
Navar. 29:59–76. 2006.PubMed/NCBI
|
|
55.
|
Kikuchi T, Toyota M, Itoh F, et al:
Inactivation of p57KIP2 by regional promoter hypermethylation and
histone deacetylation in human tumors. Oncogene. 21:2741–2749.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Perucho M: Tumors with microsatellite
instability: many mutations, targets and paradoxes. Oncogene.
22:2223–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Kaz A, Kim YH, Dzieciatkowski S, et al:
Evidence for the role of aberrant DNA methylation in the
pathogenesis of Lynch syndrome adenomas. Int J Cancer.
120:1922–1929. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Boland CR, Thibodeau SN, Hamilton SR, et
al: A National Cancer Institute Workshop on Microsatellite
Instability for cancer detection and familial predisposition:
development of international criteria for the determination of
microsatellite instability in colorectal cancer. Cancer Res.
58:5248–5257. 1998.
|
|
59.
|
Perucho M: Correspondence ref: Boland CR,
et al. A National Cancer Institute workshop on
microsatellite instability for cancer detection and familial
predisposition: development of international criteria for the
determination of microsatellite instability in colorectal cancer.
Cancer Res 58: 5248–5257, 1998. Cancer Res. 59:249–256. 1999.
|
|
60.
|
Hoang JM, Cottu PH, Thuille B, Salmon RJ,
Thomas G and Hamelin R: BAT-26, an indicator of the replication
error phenotype in colorectal cancers and cell lines. Cancer Res.
57:300–303. 1997.PubMed/NCBI
|
|
61.
|
Ribic CM, Sargent DJ, Moore MJ, et al:
Tumor microsatellite-instability status as a predictor of benefit
from fluorouracil-based adjuvant chemotherapy for colon cancer. N
Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Lothe RA, Peltomaki P, Meling GI, et al:
Genomic instability in colorectal cancer: relationship to
clinicopathological variables and family history. Cancer Res.
53:5849–5852. 1993.PubMed/NCBI
|
|
63.
|
Nishihara S, Hayashida T, Mitsuya K, et
al: Multipoint imprinting analysis in sporadic colorectal cancers
with and without micro-satellite instability. Int J Oncol.
17:317–322. 2000.PubMed/NCBI
|
|
64.
|
Nakagawa H, Chadwick RB, Peltomaki P,
Plass C, Nakamura Y and de La Chapelle A: Loss of imprinting of the
insulin-like growth factor II gene occurs by biallelic methylation
in a core region of H19-associated CTCF-binding sites in colorectal
cancer. Proc Natl Acad Sci USA. 98:591–596. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Sasaki J, Konishi F, Kawamura YJ, Kai T,
Takata O and Tsukamoto T: Clinicopathological characteristics of
colorectal cancers with loss of imprinting of insulin-like growth
factor 2. Int J Cancer. 119:80–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Lee MH, Reynisdottir I and Massague J:
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique
domain structure and tissue distribution. Genes Dev. 9:639–649.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Reid LH, Crider-Miller SJ, West A, Lee MH,
Massague J and Weissman BE: Genomic organization of the human
p57KIP2 gene and its analysis in the G401 Wilms’ tumor assay.
Cancer Res. 56:1214–1218. 1996.PubMed/NCBI
|
|
69.
|
Orlow I, Iavarone A, Crider-Miller SJ, et
al: Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue
sarcomas and Wilms’ tumors. Cancer Res. 56:1219–1221. 1996.
|
|
70.
|
Hatada I and Mukai T: Genomic imprinting
of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat
Genet. 11:204–206. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Hatada I, Inazawa J, Abe T, et al: Genomic
imprinting of human p57KIP2 and its reduced expression in Wilms’
tumors. Hum Mol Genet. 5:783–788. 1996.
|
|
72.
|
Cost GJ, Thompson JS, Reichard BA, Lee JY
and Feinberg AP: Lack of imprinting of three human cyclin-dependent
kinase inhibitor genes. Cancer Res. 57:926–929. 1997.PubMed/NCBI
|
|
73.
|
Matsuoka S, Thompson JS, Edwards MC, et
al: Imprinting of the gene encoding a human cyclin-dependent kinase
inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci USA.
93:3026–3030. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Thompson JS, Reese KJ, DeBaun MR, Perlman
EJ and Feinberg AP: Reduced expression of the cyclin-dependent
kinase inhibitor gene p57KIP2 in Wilms’ tumor. Cancer Res.
56:5723–5727. 1996.
|
|
75.
|
Ito Y, Takeda T, Sakon M, Tsujimoto M,
Monden M and Matsuura N: Expression of p57/Kip2 protein in
hepatocellular carcinoma. Oncology. 61:221–225. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Shin JY, Kim HS, Lee KS, et al: Mutation
and expression of the p27KIP1 and p57KIP2 genes in human gastric
cancer. Exp Mol Med. 32:79–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Lai S, Goepfert H, Gillenwater AM, Luna MA
and El-Naggar AK: Loss of imprinting and genetic alterations of the
cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck
squamous cell carcinoma. Clin Cancer Res. 6:3172–3176.
2000.PubMed/NCBI
|
|
78.
|
Noura S, Yamamoto H, Sekimoto M, et al:
Expression of second class of KIP protein p57KIP2 in human
colorectal carcinoma. Int J Oncol. 19:39–47. 2001.PubMed/NCBI
|
|
79.
|
Li JQ, Wu F, Usuki H, et al: Loss of
p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol.
23:1537–1543. 2003.PubMed/NCBI
|
|
80.
|
Ito Y, Yoshida H, Nakano K, et al:
Expression of p57/Kip2 protein in normal and neoplastic thyroid
tissues. Int J Mol Med. 9:373–376. 2002.PubMed/NCBI
|
|
81.
|
Sui L, Dong Y, Ohno M, Watanabe Y,
Sugimoto K and Tokuda M: Expression of p57kip2 and its clinical
relevance in epithelial ovarian tumors. Anticancer Res.
22:3191–3196. 2002.PubMed/NCBI
|
|
82.
|
Shin JY, Kim HS, Park J, Park JB and Lee
JY: Mechanism for inactivation of the KIP family cyclin-dependent
kinase inhibitor genes in gastric cancer cells. Cancer Res.
60:262–265. 2000.PubMed/NCBI
|
|
83.
|
Gazzoli I, Loda M, Garber J, Syngal S and
Kolodner RD: A hereditary nonpolyposis colorectal carcinoma case
associated with hypermethylation of the MLH1 gene in normal tissue
and loss of heterozygosity of the unmethylated allele in the
resulting micro-satellite instability-high tumor. Cancer Res.
62:3925–3928. 2002.
|
|
84.
|
Suter CM, Martin DI and Ward RL: Germline
epimutation of MLH1 in individuals with multiple cancers. Nat
Genet. 36:497–501. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
85.
|
Hitchins M, Williams R, Cheong K, et al:
MLH1 germline epimutations as a factor in hereditary nonpolyposis
colorectal cancer. Gastroenterology. 129:1392–1399. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
86.
|
Hitchins MP, Wong JJ, Suthers G, et al:
Inheritance of a cancer-associated MLH1 germ-line epimutation. N
Engl J Med. 356:697–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87.
|
Kolonel LN: Cancer patterns of four ethnic
groups in Hawaii. J Natl Cancer Inst. 65:1127–1139. 1980.PubMed/NCBI
|
|
88.
|
Kmet J: The role of migrant population in
studies of selected cancer sites: a review. J Chronic Dis.
23:305–324. 1970. View Article : Google Scholar : PubMed/NCBI
|
|
89.
|
Slattery ML, Potter JD, Samowitz W,
Schaffer D and Leppert M: Methylenetetrahydrofolate reductase, diet
and risk of colon cancer. Cancer Epidemiol Biomarkers Prev.
8:513–518. 1999.PubMed/NCBI
|
|
90.
|
Hubner RA and Houlston RS: Folate and
colorectal cancer prevention. Br J Cancer. 100:233–239. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
91.
|
Feinberg AP, Gehrke CW, Kuo KC and Ehrlich
M: Reduced genomic 5-methylcytosine content in human colonic
neoplasia. Cancer Res. 48:1159–1161. 1988.PubMed/NCBI
|
|
92.
|
Giovannucci E: Epidemiologic studies of
folate and colorectal neoplasia: a review. J Nutr. 132:S2350–S2355.
2002.
|
|
93.
|
Chen J, Giovannucci E, Kelsey K, et al: A
methylenetetrahydrofolate reductase polymorphism and the risk of
colorectal cancer. Cancer Res. 56:4862–4864. 1996.PubMed/NCBI
|
|
94.
|
Frosst P, Blom HJ, Milos R, et al: A
candidate genetic risk factor for vascular disease: a common
mutation in methylenetetrahydrofolate reductase. Nat Genet.
10:111–113. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
95.
|
Ma J, Stampfer MJ, Giovannucci E, et al:
Methylenetetrahydrofolate reductase polymorphism, dietary
interactions and risk of colorectal cancer. Cancer Res.
57:1098–1102. 1997.PubMed/NCBI
|
|
96.
|
Chen J, Giovannucci E, Hankinson SE, et
al: A prospective study of methylenetetrahydrofolate reductase and
methionine synthase gene polymorphisms, and risk of colorectal
adenoma. Carcinogenesis. 19:2129–2132. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
97.
|
Pande M, Chen J, Amos CI, Lynch PM,
Broaddus R and Frazier ML: Influence of methylenetetrahydrofolate
reductase gene polymorphisms C677T and A1298C on age-associated
risk for colorectal cancer in a caucasian lynch syndrome
population. Cancer Epidemiol Biomarkers Prev. 16:1753–1759. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
98.
|
Osian G, Procopciuc L and Vlad L: MTHFR
polymorphisms as prognostic factors in sporadic colorectal cancer.
J Gastrointestin Liver Dis. 16:251–256. 2007.PubMed/NCBI
|
|
99.
|
Shannon B, Gnanasampanthan S, Beilby J and
Iacopetta B: A polymorphism in the methylenetetrahydrofolate
reductase gene predisposes to colorectal cancers with
microsatellite instability. Gut. 50:520–524. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
100.
|
Hubner RA, Lubbe S, Chandler I and
Houlston RS: MTHFR C677T has differential influence on risk of MSI
and MSS colorectal cancer. Hum Mol Genet. 16:1072–1077. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
101.
|
Oyama K, Kawakami K, Maeda K, Ishiguro K
and Watanabe G: The association between methylenetetrahydrofolate
reductase polymorphism and promoter methylation in proximal colon
cancer. Anticancer Res. 24:649–654. 2004.
|
|
102.
|
Kawakami K, Ruszkiewicz A, Bennett G,
Moore J, Watanabe G and Iacopetta B: The folate pool in colorectal
cancers is associated with DNA hypermethylation and with a
polymorphism in methylenetetrahydrofolate reductase. Clin Cancer
Res. 9:5860–5865. 2003.PubMed/NCBI
|
|
103.
|
Clarizia AD, Bastos-Rodrigues L, Pena HB,
et al: Relationship of the methylenetetrahydrofolate reductase
C677T polymorphism with microsatellite instability and promoter
hypermethylation in sporadic colorectal cancer. Genet Mol Res.
5:315–322. 2006.PubMed/NCBI
|
|
104.
|
Eaton AM, Sandler R, Carethers JM,
Millikan RC, Galanko J and Keku TO: 5,10-Methylenetetrahydrofolate
reductase 677 and 1298 polymorphisms, folate intake, and
microsatellite instability in colon cancer. Cancer Epidemiol
Biomarkers Prev. 14:2023–2029. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
105.
|
Li YN, Gulati S, Baker PJ, Brody LC,
Banerjee R and Kruger WD: Cloning, mapping and RNA analysis of the
human methionine synthase gene. Hum Mol Genet. 5:1851–1858. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
106.
|
Chen LH, Liu ML, Hwang HY, Chen LS,
Korenberg J and Shane B: Human methionine synthase. cDNA cloning,
gene localization and expression. J Biol Chem. 272:3628–3634. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
107.
|
Ma J, Stampfer MJ, Christensen B, et al: A
polymorphism of the methionine synthase gene: association with
plasma folate, vitamin B12, homocyst(e)ine and colorectal cancer
risk. Cancer Epidemiol Biomarkers Prev. 8:825–829. 1999.PubMed/NCBI
|
|
108.
|
Paz MF, Avila S, Fraga MF, et al:
Germ-line variants in methyl-group metabolism genes and
susceptibility to DNA methylation in normal tissues and human
primary tumors. Cancer Res. 62:4519–4524. 2002.PubMed/NCBI
|
|
109.
|
Matsuo K, Hamajima N, Hirai T, et al:
Methionine synthase reductase gene A66G polymorphism is associated
with risk of colorectal cancer. Asian Pac J Cancer Prev. 3:353–359.
2002.PubMed/NCBI
|
|
110.
|
Leclerc D, Wilson A, Dumas R, et al:
Cloning and mapping of a cDNA for methionine synthase reductase, a
flavoprotein defective in patients with homocystinuria. Proc Natl
Acad Sci USA. 95:3059–3064. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
111.
|
Olteanu H, Munson T and Banerjee R:
Differences in the efficiency of reductive activation of methionine
synthase and exogenous electron acceptors between the common
polymorphic variants of human methionine synthase reductase.
Biochemistry. 41:13378–13385. 2002. View Article : Google Scholar
|
|
112.
|
Ulrich CM, Curtin K, Potter JD, Bigler J,
Caan B and Slattery ML: Polymorphisms in the reduced folate
carrier, thymidylate synthase, or methionine synthase and risk of
colon cancer. Cancer Epidemiol Biomarkers Prev. 14:2509–2516. 2005.
View Article : Google Scholar : PubMed/NCBI
|
